Dunmire SK, Verghese PS, Balfour HH. Jr. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84–92. https://doi.org/10.1016/j.jcv.2018.03.001.
Article
PubMed
Google Scholar
Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821. https://doi.org/10.1146/annurev-immunol-032414-112326.
Article
CAS
PubMed
Google Scholar
Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017;8:1867. https://doi.org/10.3389/fimmu.2017.01867.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sawada A, Inoue M. Hematopoietic stem cell transplantation for the treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders. Front Pediatr. 2018;6:334. https://doi.org/10.3389/fped.2018.00334.
Article
PubMed
PubMed Central
Google Scholar
Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev Oncol Hematol. 2002;44(3):273–82. https://doi.org/10.1016/s1040-8428(02)00118-x.
Article
PubMed
Google Scholar
Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527–33. https://doi.org/10.1086/367988.
Article
PubMed
Google Scholar
Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–49. https://doi.org/10.1182/blood-2010-11-316745.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ebihara Y, Manabe A, Tanaka R, Yoshimasu T, Ishikawa K, Iseki T, et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;31(12):1169–71. https://doi.org/10.1038/sj.bmt.1704078.
Article
CAS
PubMed
Google Scholar
Taketani T, Kikuchi A, Inatomi J, Hanada R, Kawaguchi H, Ida K, et al. Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;29(6):531–3. https://doi.org/10.1038/sj.bmt.1703392.
Article
CAS
PubMed
Google Scholar
Fujii N, Takenaka K, Hiraki A, Maeda Y, Ikeda K, Shinagawa K, et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant. 2000;26(7):805–8. https://doi.org/10.1038/sj.bmt.1702600.
Article
CAS
PubMed
Google Scholar
Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for Leukemia. Clin Cancer Res. 2015;21(9):2020–8. https://doi.org/10.1158/1078-0432.CCR-14-0586.
Article
PubMed
Google Scholar
Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD Consortium. Blood. 2011;117(17):4651–7. https://doi.org/10.1182/blood-2010-11-319509.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24(11):1852–8. https://doi.org/10.1038/leu.2010.187.
Article
CAS
PubMed
Google Scholar
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for blood and marrow transplantation. Lancet Haematol. 2020;7(2):e157-e67. https://doi.org/10.1016/S2352-3026(19)30256-X.
Article
Google Scholar
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168–73. https://doi.org/10.1038/bmt.2013.107.
Article
CAS
PubMed
Google Scholar
Dou L, Hou C, Ma C, Li F, Gao X, Huang W, et al. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Ann Hematol. 2020;99(1):167–79. https://doi.org/10.1007/s00277-019-03884-8.
Article
PubMed
Google Scholar
Zuckerman T, Rowe JM. Alternative donor transplantation in acute myeloid leukemia: which source and when? Curr Opin Hematol. 2007;14(2):152–61. https://doi.org/10.1097/MOH.0b013e328017f64d.
Article
PubMed
Google Scholar
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep. 2011;3(Suppl 2):e15. https://doi.org/10.4081/pr.2011.s2.e15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482–9. https://doi.org/10.1016/j.bbmt.2009.11.011.
Article
CAS
PubMed
PubMed Central
Google Scholar
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–30. https://doi.org/10.1182/blood-2009-11-251595.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bailen R, Kwon M, Pascual-Cascon MJ, Ferra C, Sanz J, Gallardo-Morillo A, et al. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Ann Hematol. 2021;100(2):541–53. https://doi.org/10.1007/s00277-020-04317-7.
Article
CAS
PubMed
Google Scholar
Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918–26. https://doi.org/10.1182/bloodadvances.2020001451.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022;97(6):780–90. https://doi.org/10.1002/ajh.26544.
Article
CAS
PubMed
Google Scholar
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-8.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401 e1. https://doi.org/10.1016/j.bbmt.2014.12.001.
Article
PubMed
Google Scholar
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–48. https://doi.org/10.1056/NEJMsa1311707.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10–24. https://doi.org/10.1038/nrclinonc.2015.128.
Article
CAS
PubMed
Google Scholar
Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–77. https://doi.org/10.1200/JCO.1997.15.5.1767.
Article
CAS
PubMed
Google Scholar
Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, et al. Haploidentical hematopoietic stem cell transplantation: A global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016;22(1):23–6. https://doi.org/10.1016/j.bbmt.2015.11.001.
Article
PubMed
Google Scholar
Maegaki M, Kawamura K, Hara K, Hosoda R, Suzuki S, Hosoda Y, et al. Successful HLA-haploidentical stem cell transplantation with post-transplant cyclophosphamide in an older patient with chronic active Epstein-Barr virus infection. Int J Hematol. 2022;116(4):630–4. https://doi.org/10.1007/s12185-022-03345-5.
Article
CAS
PubMed
Google Scholar
Battipaglia G, Labopin M, Kroger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134(11):892–9. https://doi.org/10.1182/blood.2019000487.
Article
CAS
PubMed
Google Scholar
Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–18. :https://doi.org/10.1007/s12185-017-2192-6.
Article
CAS
PubMed
Google Scholar
Song Y, Yin Z, Ding J, Wu T. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation is a good choice for Acute myeloid leukemia and myelodysplastic syndrome: a Meta-analysis of Randomized controlled trials. Front Oncol. 2021;11:708727. https://doi.org/10.3389/fonc.2021.708727.
Article
PubMed
PubMed Central
Google Scholar
Arcuri LJ, Hamerschlak N, Rocha V, Bonfim C, Kerbauy MN. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts. Transplant Cell Ther. 2021;27(9):782 e1- e7. https://doi.org/10.1016/j.jtct.2021.06.011.
Kawa K, Sawada A, Sato M, Okamura T, Sakata N, Kondo O, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplat. 2011;46(1):77–83. https://doi.org/10.1038/bmt.2010.122.
Article
CAS
Google Scholar
Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–73. https://doi.org/10.1172/JCI124218.
Article
PubMed
PubMed Central
Google Scholar
Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247–62. https://doi.org/10.1182/blood-2017-05-780668.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nakamae H, Fujii K, Nanno S, Okamura H, Nakane T, Koh Hideo, et al. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors. Transpl Int. 2019;32(12):1322–32. doi:https://doi.org/10.1111/tri.13494.
Article
CAS
PubMed
Google Scholar
Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE, et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood. 2015;125(18):2855–64. https://doi.org/10.1182/blood-2014-11-608406.
Article
CAS
PubMed
PubMed Central
Google Scholar
Williams L, Cirrone F, Cole K, Abdul-Hay M, Luznik L, Al-Homsi AS. Post-transplantation cyclophosphamide: from HLA-Haploidentical to matched-related and matched-unrelated Donor blood and marrow transplantation. Front Immunol. 2020;11:636. https://doi.org/10.3389/fimmu.2020.00636.
Article
CAS
PubMed
PubMed Central
Google Scholar